Health Care Use, Costs, and Survival Trajectory of Home Mechanical Insufflation-Exsufflation.

costs cough assist health care utilization mechanical insufflation-exsufflation neuromuscular disease

Journal

Respiratory care
ISSN: 1943-3654
Titre abrégé: Respir Care
Pays: United States
ID NLM: 7510357

Informations de publication

Date de publication:
02 2022
Historique:
pubmed: 22 10 2021
medline: 29 3 2022
entrez: 21 10 2021
Statut: ppublish

Résumé

Despite expert recommendations for use, limited evidence identifies effectiveness of mechanical insufflation-exsufflation (MI-E) in addressing respiratory morbidity and resultant health care utilization and costs for individuals with neuromuscular disorders. We examined the impact of provision of publicly funded MI-E devices on health care utilization, health care costs, and survival trajectory. This is a retrospective pre/post cohort study linking data on prospectively recruited participants using MI-E to health administrative databases to quantify outcomes. We linked data from 106 participants (8 age < 15 y) and determined annualized health care use pre/post device. We found no difference in emergency department (ED) visit or hospital admission rates. Following MI-E approval, participants required fewer hospital days (median [interquartile range] [IQR]) 0 [0-9] vs 0 [0-4], Provision of publicly funded MI-E devices did not influence rates of ED visits or hospital admission but did shift health care utilization and costs from the acute care to community sector. Although increased community costs negated cost savings from physician billings, evidence suggests costs savings from reduced hospital days and fewer specialist visits. Risk of death was highest in individuals requiring multiple medical technologies.

Sections du résumé

BACKGROUND
Despite expert recommendations for use, limited evidence identifies effectiveness of mechanical insufflation-exsufflation (MI-E) in addressing respiratory morbidity and resultant health care utilization and costs for individuals with neuromuscular disorders. We examined the impact of provision of publicly funded MI-E devices on health care utilization, health care costs, and survival trajectory.
METHODS
This is a retrospective pre/post cohort study linking data on prospectively recruited participants using MI-E to health administrative databases to quantify outcomes.
RESULTS
We linked data from 106 participants (8 age < 15 y) and determined annualized health care use pre/post device. We found no difference in emergency department (ED) visit or hospital admission rates. Following MI-E approval, participants required fewer hospital days (median [interquartile range] [IQR]) 0 [0-9] vs 0 [0-4],
CONCLUSIONS
Provision of publicly funded MI-E devices did not influence rates of ED visits or hospital admission but did shift health care utilization and costs from the acute care to community sector. Although increased community costs negated cost savings from physician billings, evidence suggests costs savings from reduced hospital days and fewer specialist visits. Risk of death was highest in individuals requiring multiple medical technologies.

Identifiants

pubmed: 34670856
pii: respcare.09263
doi: 10.4187/respcare.09263
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

191-200

Informations de copyright

Copyright © 2022 by Daedalus Enterprises.

Déclaration de conflit d'intérêts

The authors disclose a relationship with IQVIA Canada.

Auteurs

Louise Rose (L)

Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, London, United Kingdom. louise.rose@kcl.ac.uk.

Tom Fisher (T)

Ventilator Equipment Pool, Kingston, Canada.

Regina Pizzuti (R)

Ventilator Equipment Pool, Kingston, Canada.

Reshma Amin (R)

Division of Respiratory Medicine, Hospital for Sick Children (SickKids) and SickKids Research Institute, University of Toronto, Toronto, Canada.

Ruth Croxford (R)

ICES, Toronto, Canada.

Craig M Dale (CM)

Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada; and Department of Critical Care, Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto, Canada.

Roger Goldstein (R)

West Park Healthcare Centre, Toronto, Canada and also affiliated with the Faculty of Medicine, University of Toronto, Toronto, Canada.

Sherri Katz (S)

Children's Hospital of Eastern Ontario and Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.

David Leasa (D)

Department of Medicine, Divisions of Critical Care and Respirology, London Health Sciences Centre, London, Canada; and Faculty of Medicine, Western University, London, Canada.

Doug McKim (D)

The Ottawa Hospital Respiratory Rehabilitation and The Ottawa Hospital Sleep Centre and Ottawa Hospital Research Institute, Ottawa, Canada and also affiliated with the Faculty of Medicine, University of Ottawa, Ottawa, Canada.

Mika Nonoyama (M)

Faculty of Health Sciences, Ontario Tech University, Oshawa, Canada and also affiliated with the Rehabilitation Sciences Institute, University of Toronto, Toronto, Canada.

Anu Tandon (A)

Division of Respirology, Sunnybrook Health Sciences Centre and also affiliated with the Faculty of Medicine, University of Toronto, Toronto, Canada.

Andrea Gershon (A)

Division of Respirology, Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto, Canada; ICES, Toronto, Canada and also affiliated with the Faculty of Medicine, University of Toronto, Toronto, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH